Upper-Extremity Arterial Disease, Hand Ischemia, Raynaud/Buerger Interface, and Repetitive Injury
Upper-extremity arterial disease and hand ischemia approached by mechanism rather than as a generic cold or blue hand: proximal inflow disease, distal vasospasm, repetitive-trauma arteriopathy, Buerger disease, and inflammatory distal-vessel disease. The chapter frames diagnostic workup and intervention thresholds for each.
Planning conference: A practical planning-room conversation: anatomy, device or operative choices, surveillance, complications, and decision boundaries.
General medical education, not patient-specific advice.
Choose the hostsDefinition and clinical presentation
Upper-extremity arterial disease encompasses proximal atherosclerotic occlusive disease, distal vasospasm, inflammatory distal-vessel disease, repetitive-trauma arteriopathy, and traumatic arterial injury . Presenting features govern the diagnostic and therapeutic approach:
- Bilateral digital vasospasm suggests primary Raynaud phenomenon.
- Vasospasm with multiple digital ulcers indicates secondary Raynaud phenomenon, often associated with systemic sclerosis.
- Unilateral hand ischemia with hypothenar trauma points to hypothenar hammer syndrome.
- Ischemia with occupational vibratory exposure suggests hand-arm vibration syndrome.
- Distal ischemia in young tobacco users indicates thromboangiitis obliterans (Buerger disease).
- Sudden embolic or thrombotic limb threat presents as acute limb ischemia.
Diagnosis and evaluation
Diagnostic evaluation isolates the anatomic level and identifies the mechanism of ischemia. For suspected hypothenar hammer syndrome, the modified Allen test serves as a bedside screening tool; delayed or absent palmar refill on ulnar release indicates ulnar artery and superficial palmar arch occlusion . Duplex ultrasonography paired with catheter or computed tomography angiography confirms the diagnosis by demonstrating segmental ulnar artery occlusion, corkscrew morphology, or focal aneurysmal dilation at the hook of the hamate .
Hand-arm vibration syndrome assessment requires verification of exposure-response thresholds and individual host risk factors, supplemented by modality-specific imaging such as Tc-99m hand perfusion scintigraphy . In thromboangiitis obliterans, intravenous iloprost response is quantifiable using computed tomography perfusion imaging to demonstrate distal flow changes . Because visceral involvement occurs in thromboangiitis obliterans, broader evaluation is required when symptoms extend beyond the extremity .
Management and revascularization thresholds
Upper-extremity arterial management requires primary and secondary prevention tailored to the disease mechanism, with targeted revascularization reserved for threatened tissue or severe lifestyle-limiting symptoms. The treatment logic prioritizes medical and risk-factor modification before procedural intervention.
Atherosclerotic PAD
- Threshold or trigger
- Symptomatic subclavian or axillary disease
- Preferred management
- Medical optimization with single antiplatelet therapy; revascularization for severe symptoms
CitationHigh-risk atherosclerotic PAD
- Threshold or trigger
- High ischemic risk with acceptable bleeding risk
- Preferred management
- Rivaroxaban plus aspirin
CitationTraumatic arterial injury
- Threshold or trigger
- Acute injury pattern and distal ischemia
- Preferred management
- Tailored primary repair, bypass grafting, or endovascular intervention
CitationPrimary Raynaud
- Threshold or trigger
- Bothersome vasospastic attacks
- Preferred management
- Core warming, cold avoidance, and calcium-channel blockers
CitationSecondary Raynaud
- Threshold or trigger
- Systemic sclerosis with multiple digital ulcers
- Preferred management
- Bosentan to reduce new ulcer development
CitationBuerger disease
- Threshold or trigger
- Diagnosis of thromboangiitis obliterans
- Preferred management
- Complete tobacco abstinence
Citation
Management of upper-extremity ischemia follows a mechanism-specific stepwise algorithm:
- Confirm the disease mechanism and treat systemic risk factors: establish single antiplatelet therapy for atherosclerotic disease, mandate complete smoking cessation for Buerger disease, and initiate core warming and cold avoidance for vasospastic disease.
- Determine the need for pharmacologic escalation: add calcium-channel blockers for primary Raynaud, or bosentan for recurrent digital ulcers in systemic sclerosis.
- Evaluate anatomical suitability for intervention: reserve open or endovascular revascularization for severe atherosclerotic symptoms, aneurysmal degeneration in hypothenar hammer syndrome, or tissue loss.
- Identify acute trauma or acute limb threat: abandon the elective algorithm for immediate operative repair, bypass grafting, or endovascular recanalization based on the specific injury pattern rather than standard atherosclerotic protocols.
Raynaud phenomenon and digital ulcers
Primary Raynaud phenomenon is a highly prevalent clinical phenotype rather than a diagnosis of exclusion . Foundational management requires core warming, smoking cessation, avoidance of cold exposure, and the minimization of vasoconstrictor medications before pharmacologic escalation . First-line pharmacotherapy relies on calcium-channel blockers, with other vasodilator classes serving as secondary options .
In patients with systemic sclerosis and a history of multiple digital ulcers, the endothelin-receptor antagonist bosentan reduces the development of new digital ulcers, based on the RAPIDS-1 and RAPIDS-2 trials . Dose bosentan 62.5 mg twice daily for 4 weeks, then 125 mg twice daily. In RAPIDS-2 it cut the mean number of new digital ulcers over 24 weeks by roughly 30% (1.9 versus 2.7, p=0.04) but did not improve healing of established ulcers . Monitor liver enzymes monthly. European society guidelines advocate a unified diagnostic framework that places Raynaud, hand ischemia, and upper-extremity peripheral arterial disease within a single vascular disease spectrum to ensure coordinated secondary prevention .
Buerger disease (thromboangiitis obliterans)
Thromboangiitis obliterans is a tobacco-linked distal ischemic disease in which complete tobacco abstinence is the primary limb-preservation intervention. Continued tobacco use is associated with progressive ischemic events and limb loss in approximately half of patients, whereas complete abstinence stabilizes the disease in the majority . Pharmacologic options have limited efficacy; endothelin-receptor antagonists demonstrate uncertain effects on digital perfusion and ulcer healing, precluding their routine use .
Occupational and repetitive trauma
Repetitive occupational exposure drives both hand-arm vibration syndrome and hypothenar hammer syndrome. Hand-arm vibration exposure correlates with distinct vascular and neurologic disease outcomes . Persistent vibration exposure with vascular symptoms necessitates direct occupational exposure reduction and monitoring, as the risk is shaped by cumulative dose and individual susceptibility . Hypothenar hammer syndrome requires identification of ulnar artery damage at the hook of the hamate, with intervention directed by the degree of occlusion or aneurysmal change rather than generalized vasodilator therapy .
Areas of controversy
Device selection for subclavian artery stenosis lacks comparative trial data; there are no completed or ongoing randomized controlled trials comparing angioplasty to stenting . While contemporary cohort data signal effective outcomes for primary covered-stent implantation in supra-aortic arch and subclavian occlusive disease, randomized superiority remains unproven .
For hypothenar hammer syndrome presenting with acute or subacute occlusion, evidence for endovascular thrombolysis is restricted to small retrospective series and case reports, limited by selection bias and heterogeneity in lytic agent, dose, and duration . In refractory Raynaud phenomenon, botulinum toxin A injection is an emerging procedural modality; its evidence base remains confined to narrative reviews and case series distinct from established vasodilator trials .
References
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review. 2023.PubMed-indexed articleMeta-analysis / systematic review2023
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review. 2023. doi:10.1093/rheumatology/kead289.
- 15.Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences. 2021.PubMed-indexed articleReview2021
Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences. 2021. doi:10.3390/diagnostics11101736.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.Matucci-Cerinic M, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32-38.PubMed-indexed article2011
Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32-38. doi:10.1136/ard.2010.130658.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.